| abstract |
REFERS TO COMPOUNDS DERIVED FROM PIPERIDINE OF FORMULA (I), WHERE R1 IS ALKYL (C1-C6) OPTIONALLY SUBSTITUTED BY AY, AND / OR BY PHENYL, HETEROARYL, NRCRD, CYCLOALKYL (C3-C7), BETWEEN CICLO OR C3-C10), ALKINYL (C2-C6), HETEROCYCLIC, AMONG OTHERS; Ra IS H, ALKYL (C1-C4), AMONG OTHERS; Rb IS H; R2 IS H, HALO, CYANE, (C1-C3) ALKYL, AMONG OTHERS; R3 IS H, HALO, CYANE, (C1-C3) ALKYL, AMONG OTHERS; R4 IS CYANE, HALO, ALKYLSULFONYL (C1-C4); R7 IS H O HYDROXY, AMONG OTHERS. 1-BUTYL-3- [5- [4- (4-CYANOPHENYL) PIPERIDIN-1-CARBONYL] -2-METHYL-PHENYL] UREA, 3-BENZYL-1- [5- [4- (4-CYANOPHENYL) ) PIPERIDIN-1-CARBONYL] -2- (TRIFLUOROMETOXI) PHENYL] UREA, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION AND A PREPARATION PROCEDURE. THESE COMPOUNDS ARE INHIBITORS OF FATTY ACID SYNTHASE (FAS), BEING USEFUL IN THE TREATMENT OF OBESITY AND DIABETES MELLITUS |